Purpose. Cardiogenic shock (CS) is the leading cause of death in patients with acute myocardial infarction (AMI). Our study aimed to evaluate the short-term prognostic value of admission blood urea nitrogen (BUN) in patients with CS complicating AMI. Materials and Methods. 218 consecutive patients with CS after AMI were enrolled. The primary endpoint was 30-day mortality. The association of admission BUN and 30-day mortality and major adverse cardiovascular event (MACE) was investigated by Cox regression. The integrated discrimination improvement (IDI) and net reclassification improvement (NRI) further examined the predictive value of BUN.

Results. During a period of 30-day follow-up, 105 deaths occurred. Compared to survivors, nonsurvivors had significantly higher admission BUN ($p < 0.001$), creatinine ($p < 0.001$), BUN/creatinine ($p = 0.03$), and a lower glomerular filtration rate ($p < 0.001$). The area under the curve (AUC) of the 4 indices for predicting 30-day mortality was 0.781, 0.734, 0.588, and 0.773, respectively. When compared to traditional markers associated with CS, the AUC for predicting 30-day mortality of BUN, lactate, and left ventricular ejection fraction were 0.781, 0.776, and 0.701, respectively. The optimal cut-off value of BUN for predicting 30-day mortality was 8.95 mmol/L with Youden-Index analysis. Multivariate Cox analysis indicated BUN $> 8.95$ mmol/L was an important independent predictor for 30-day mortality (HR 2.08, 95%CI 1.28–3.36, $p < 0.003$) and 30-day MACE (HR 1.85, 95%CI 1.29–2.66, $p = 0.001$). IDI (0.053, $p = 0.005$) and NRI (0.135, $p = 0.010$) showed an improvement in the accuracy for mortality prediction of the new model when BUN was included compared with the standard model of predictors in previous scores.

Conclusion. An admission BUN $> 8.95$ mmol/L was robustly associated with increased short-term mortality and MACE in patients with CS after AMI. The prognostic value of BUN was superior to other renal markers and comparable to traditional markers. This easily accessible index might be promising for early risk stratification in CS patients following AMI.

1. Introduction

Acute myocardial infarction (AMI) complicated by cardiogenic shock (CS) is a high-acuity and complex state of end-organ hypoperfusion that is frequently associated with multisystem organ failure. Despite advances in therapeutic options in recent years, mortality remains high [1, 2]. To assist the triage of patients for specific therapies and to determine prognosis, many investigators have evaluated the predictors of mortality in CS patients. However, there was a wide heterogeneity among these studies, and not all important variables were analyzed [3].

The markers of renal function are known to be closely related to the outcomes in cardiovascular disorders [4, 5]. Routine parameters used for evaluating patients’ renal function usually include blood urea nitrogen (BUN), creatinine, glomerular filtration rate (GFR), and sometimes the ratio of BUN and creatinine [6]. While both BUN and creatinine are filtrated through the glomerulus and can reflect GFR, only BUN is reabsorbed from the tubules [6, 7]. In heart failure patients, it was found that elevated BUN was not only a result of damaged renal function but also related to enhanced urea reabsorption because of neurohumoral activation [8]. In fact, BUN has been shown to be an independent predictor of postdischarge all-cause mortality in elderly patients with acute decompensated heart failure, and its prognostic performance was similar to that of B-type natriuretic peptide (BNP) [9].
CS is regarded as the most severe heart failure status after AMI, whereas the association between BUN and the outcome in patients with CS after AMI has not been well-studied. Accordingly, the present study aimed to evaluate the admission BUN in CS complicating AMI for prognostic relevance and to compare its predictive value with renal biomarkers and other well-acknowledged predictors in this population.

2. Materials and Methods

It is a retrospective study that is aimed to evaluate the short-term outcomes in patients who developed CS after AMI. The data of consecutive patients diagnosed with AMI in our hospital between January 2013 and September 2020 were collected from the computerized patient record system. Then, patients whose clinical presentation and laboratory examination were in accord with CS were further screened according to the definition of CS [10]. Finally, a total of 245 consecutive patients diagnosed with AMI complicated by CS were identified. AMI was diagnosed when there is a rise and/or fall of cardiac troponin values with at least 1 value above the 99th percentile upper reference limit and at least 1 of the following: symptoms of myocardial ischemia, new ischemic electrocardiogram (ECG) changes, the development of pathological Q waves, imaging evidence of a new loss of viable myocardium, or new regional wall motion abnormality in a pattern consistent with ischemic etiology [11]. CS was defined as the systolic blood pressure (SBP) <90 mmHg under pharmacological and/or mechanical support to maintain SBP ≥90 mmHg, the evidence of end-organ hypoperfusion, such as urine output <30 ml/h, cool extremities, altered mental status, and/or serum lactate >2.0 mmol/L [10]. This study was performed in accordance with the principle of the Declaration of Helsinki, and the research protocol was approved by the institutional ethical review board of The First Affiliated Hospital of Chongqing Medical University (No. 2020-233).

Baseline, laboratory, and procedural data were all extracted from the electronic medical system by experienced doctors and nurses. Baseline characteristics, including age, gender, body mass index, medical histories, clinical presentations, and vital signs, were recorded on admission. Laboratory data, including arterial blood gas, BUN, serum creatinine, cardiac enzymes, and BNP, were also obtained on admission. The reference range of our laboratory for BUN was 3.6–9.5 mmol/L and 57–111 μmol/L, respectively. GFR was calculated by the CKD-EPI equation, an equation that was proposed in 2009, which is now regarded as one of the most recommended equations for estimated GFR [12]. After admission, patients were given acute coronary artery angiography unless contraindication existed or refused by patients, and the characteristics of the coronary artery were collected. The culprit vessels were treated according to the recommendations for the management of CS complicating AMI [13]. After the intervention procedure, patients were sent to the coronary care unit for electrocardiogram monitoring and further management. Vasoactive agents, antiplatelet drugs, statins, β-blockers, angiotensin-converting enzyme inhibitor (ACEI)/angiotensin-converting receptor blocker (ARB), proton pump inhibitor, and other medications were administered according to the guidelines [2, 14].

The primary endpoint of the study was all-cause mortality during the 30-day follow-up. The second endpoint was major adverse cardiovascular events (MACE) that included all-cause mortality, ventricular tachycardia or fibrillation (VT/VF), high-grade atrioventricular block (AVB), and nonfatal stroke during the 30-day follow-up.

The analysis of normality was performed for continuous variables with Kolmogorov–Smirnov test. Continuous variables that were normally distributed were expressed as mean ± standard deviation (SD) and compared with t-test, while non-normally-distributed data were expressed as median with interquartile range (IQR) and compared with Mann–Whitney U test. Categorical variables were presented as frequency (percentage) and compared using the Pearson chi-square test. To identify the predictive value of BUN, creatinine, BUN-to-creatinine ratio, and GFR, the receiver operating characteristic curve (ROC) was adopted, and the area under the curve (AUC) for 30-day mortality and 30-day MACE were calculated. The ROC of BUN was also compared to arterial lactate and left ventricular ejection fraction (LVEF). Patients were then divided into 2 groups according to the cut-off value of BUN determined by the Youden-index. The primary and secondary outcomes were compared between the 2 groups. Then, Kaplan–Meier analysis by quartiles and cut-off of BUN was employed to compare all-cause mortality and to plot time-to-event curves, and the comparisons of the curves were achieved by log-rank test. To evaluate and to adjust for confounding factors for 30-day mortality and MACE, a multivariate Cox proportional model was built by forward stepwise variable selection by including parameters with significant p values in the univariate analysis. In the Cox regression model, the continuous laboratory variables, including arterial lactate, troponin I (TNI), BNP, GFR, and LVEF, were all converted to categorical variables by their respective Yonden-indexes. The adjusted hazard ratios (HR) with 95% confidence intervals (CIs) were calculated. Specifically, both HRs of BUN as a continuous variable and as a categorical variable were calculated, but not at the same time. The multivariate model only included BUN as a categorical variable for analysis. Later, a standard model for 30-day mortality prediction was developed by including age, SBP, anterior myocardial infarction, lactate, and creatinine that were components of previous scores [3, 15, 16]. Then, the integrated discrimination improvement (IDI) and net reclassification improvement (NRI) were calculated to evaluate the improvement of a predictive value of a new model by replacing creatinine with BUN. Specifically, the category NRI was calculated using 20% and 40% as the thresholds to define the risk grade of 30-day mortality: low risk (<20%), intermediate risk (20–40%), and high risk (>40%), based on a previous risk stratification of CS from the IABP-SHOCK II trial [16]. All statistical analyses were carried out using the SPSS software, version 26.0 (IBM Corp. Armonk, NY, USA) or R, version 3.6.3 (R Foundation for Statistical Computing, Vienna, Austria). Statistical significance was defined as a two-sided p value <0.05.
higher in nonsurvivors.

\[ p < 0.001 \]

In terms of medications, the usages of ticagrelor \( (p = 0.02) \), statins \( (p = 0.001) \), ACEI/ARB \( (p < 0.001) \), and \( \beta \)-blocker \( (p < 0.001) \) were higher in survivors, while the usage of dopamine \( (p = 0.007) \) and norepinephrine \( (p = 0.003) \) was higher in nonsurvivors.

Table 1: Baseline characteristics and medications of the study population.

| Variables               | Total \((n = 218)\) | CS survivors \((n = 113)\) | CS nonsurvivors \((n = 105)\) | \( p \) value |
|-------------------------|---------------------|-----------------------------|-----------------------------|--------------|
| Age (years)             | 72.5 (63.78)        | 66 (59.75)                  | 75 (69.81)                  | \(< 0.001\)  |
| Male (%)                | 142 (65.1%)         | 81 (71.7%)                  | 61 (58.1%)                  | 0.04         |
| BMI (kg/m\(^2\))        | 23.1 ± 3.0          | 23.6 ± 2.9                  | 22.6 ± 3.1                  | 0.02         |
| Hypertension (%)        | 109 (50%)           | 57 (50.4%)                  | 52 (49.5%)                  | 0.89         |
| Diabetes (%)            | 73 (33.5%)          | 35 (31.0%)                  | 38 (36.2%)                  | 0.42         |
| Dyslipidemia (%)        | 15 (6.9%)           | 8 (7.1%)                    | 7 (6.7%)                    | 0.90         |
| Smoking (%)             | 115 (52.8%)         | 73 (64.6%)                  | 42 (40.0%)                  | \(< 0.001\)  |
| History of stroke (%)   | 15 (6.9%)           | 10 (9.5%)                   | 5 (4.4%)                    | 0.14         |
| History of AF (%)       | 13 (6.0%)           | 6 (5.3%)                    | 7 (6.7%)                    | 0.67         |
| Prior MI (%)            | 12 (5.5%)           | 3 (2.7%)                    | 9 (8.6%)                    | 0.06         |
| SBP (mmHg)              | 85 (78, 93)         | 87 (79, 99)                 | 85 (78, 90)                 | 0.02         |
| DBP (mmHg)              | 56 (50, 63)         | 57 (51, 64)                 | 55 (48.5, 60.5)             | 0.17         |
| Heart rate (bpm)        | 87.6 ± 28.1         | 84.1 ± 27.8                 | 91.4 ± 28.0                 | 0.06         |
| MI localization (%)     |                     |                             |                             |              |
| Anterior                | 80 (36.7%)          | 39 (34.5%)                  | 41 (39.0%)                  | 0.49         |
| Inferior                | 94 (43.1%)          | 53 (46.9%)                  | 41 (39.0%)                  | 0.24         |
| Lateral                 | 18 (8.3%)           | 7 (6.2%)                    | 11 (10.5%)                  | 0.25         |
| Right ventricle         | 27 (12.4%)          | 18 (15.9%)                  | 9 (8.6%)                    | 0.10         |
| Medications (%)         |                     |                             |                             |              |
| Aspirin                 | 201 (92.2%)         | 106 (93.8%)                 | 95 (90.5%)                  | 0.36         |
| Clopidogrel             | 114 (52.3%)         | 61 (54.0%)                  | 53 (50.5%)                  | 0.61         |
| Ticagrelor              | 115 (52.8%)         | 68 (60.2%)                  | 47 (44.8%)                  | 0.02         |
| Statins                 | 201 (92.2%)         | 111 (98.2%)                 | 90 (85.7%)                  | 0.001        |
| ACEI/ARB                | 74 (33.9%)          | 53 (46.9%)                  | 21 (20.0%)                  | \(< 0.001\)  |
| \( \beta \)-blocker    | 123 (56.4%)         | 77 (68.1%)                  | 46 (43.8%)                  | \(< 0.001\)  |
| Diuretics               | 119 (54.6%)         | 61 (54.0%)                  | 58 (55.2%)                  | 0.85         |
| Dopamine                | 106 (48.6%)         | 45 (39.8%)                  | 61 (58.1%)                  | 0.007        |
| Norepinephrine          | 30 (13.8%)          | 8 (7.1%)                    | 22 (21.0%)                  | 0.003        |
| Nitrates                | 63 (28.9%)          | 34 (30.1%)                  | 29 (27.6%)                  | 0.69         |
| Digitalis               | 28 (12.8%)          | 14 (12.4%)                  | 14 (13.3%)                  | 0.84         |

Data are expressed as mean ± SD, median (IQR) or number (percentage). CS: cardiogenic shock, BMI: body mass index, AF: atrial fibrillation, MI: myocardial infarction, SBP: systolic blood pressure, DBP: diastolic blood pressure, and ACEI/ARB: angiotensin-converting enzyme inhibitor or angiotensin receptor blocker.

3. Results

3.1. Baseline Characteristics and Medications. A total of 245 patients were diagnosed with CS complicating AMI, among which 27 patients were excluded because of incomplete data or without undergoing coronary artery angiography, and the remaining 218 patients were included in this study. They were initially divided into 2 groups according to their survival status at the end of 30-day follow-up. During a period of 30-day follow-up, 105 patients died. The baseline characteristics and medications during hospitalization are listed in Table 1. Compared to the survivors, nonsurvivors were older \( (p < 0.001) \), slightly thinner \( (p = 0.02) \), more likely to be female \( (p = 0.04) \) or nonsmokers \( (p < 0.001) \), and presented with lower SBP \( (p = 0.02) \). The history of hypertension, diabetes mellitus, dyslipidemia, stroke, and atrial fibrillation were similar between the 2 groups. As for AMI localization, there was no difference between the 2 groups.

3.2. Laboratory, Echocardiographic, and Angiographic Findings. The laboratory, echocardiographic, and angiographic findings of all patients are summarized in Table 2. Lactate, BNP, D-dimer, and white blood cell in nonsurvivors were significantly higher than in survivors (all \( p < 0.05 \)). Nonsurvivors also had lower left ventricular ejection fraction \( (LVEF) \) \( (p < 0.001) \), larger left ventricular end-diastolic dimension \( (p < 0.001) \), and more septal perforation occurrence \( (p < 0.001) \). Figure 1 compares the median with the IQR of BUN, creatinine, BUN-to-creatinine ratio, and GFR of the two groups. Compared with the survivors, nonsurvivors had significantly elevated admission BUN \( (p < 0.001) \), creatinine \( (p < 0.001) \), BUN-to-creatinine ratio \( (p = 0.03) \), and reduced GFR \( (p < 0.001) \).

3.3. Association of BUN with the Outcomes. The ROC of BUN, creatinine, BUN-to-creatinine ratio, and GFR for predicting 30-day mortality and 30-day MACE were presented in figures 2(a) and 2(b). The AUC of the 4 indexes for 30-day mortality were 0.781, 0.734, 0.588, and 0.773, respectively. The AUC for 30-day MACE were 0.744, 0.687, 0.600, and 0.702, respectively. BUN had the highest AUC for both 30-day mortality and MACE, followed by GFR. With
regard to the already known indicators of organ hypoperfusion, the AUC of arterial lactate and LVEF were 0.776 and 0.701 for 30-day mortality, 0.760 and 0.640 for 30-day MACE, as presented in figures 2(c) and 2(d).

The optimal cut-off point for BUN to predict the 30-day mortality in CS patients was determined by Yonden-index with the level of 8.95 mmol/L, with a sensitivity of 0.70, and a specificity of 0.81. The patients were then divided into 2 groups based on the cut-off value, and their outcomes were compared between the 2 groups (Figure 3). The 30-day mortality was significantly higher in the BUN >8.95 mmol/L group (76.8% vs 26.0%, \( p < 0.001 \)). Although the adverse events of VT/VF, AVB, and stroke did not differ between the 2 groups, the total MACE was significantly higher in the group with BUN >8.95 mmol/L (86.3% vs 48.8%, \( p < 0.001 \)). The Kaplan–Meier curves by quartiles (quartile 1: ≤5.9 mmol/L, quartile 2: 5.9–8.15 mmol/L, quartile 3: 8.15–14.4 mmol/L, quartile 4: >14.4 mmol/L) and by cut-off of 8.95 mmol/L for 30-day all-cause mortality were displayed in Figure 4. It was revealed that patients with higher BUN had significantly

---

**Table 2: Laboratory, echocardiographic, and angiographic findings.**

| Variables          | Total (n = 218) | CS survivors (n = 113) | CS nonsurvivors (n = 105) | \( p \) value |
|--------------------|-----------------|-----------------------|---------------------------|--------------|
| PO2 (mmHg)        | 84 (63, 110)    | 88 (64, 110)          | 79 (60.5, 111)            | 0.24         |
| PCO2 (mmHg)       | 32 (27, 37)     | 34 (28, 37.5)         | 30 (26, 37)               | 0.02         |
| Lac (mmol/L)      | 3.4 (1.9, 6.5)  | 2.3 (1.6, 3.6)        | 5.9 (3.0, 8.6)            | <0.001       |
| TNI (ng/mL)       | 4.4 (0.9, 10.9) | 3.7 (0.7, 9.9)        | 4.9 (1.3, 16.0)           | 0.15         |
| BUN >400pg/mL (%) | 129 (59.2)      | 45 (39.8)             | 84 (80.0)                 | <0.001       |
| D-dimer (ng/mL)   | 1.1 (0.6, 2.5)  | 0.8 (0.3, 1.8)        | 1.8 (0.9, 3.3)            | <0.001       |
| HbA1C (%)         | 6.3 (5.8, 7.4)  | 6.3 (5.9, 7.2)        | 6.3 (5.8, 7.8)            | 0.68         |
| WBC (× 10^9/L)    | 10.5 (7.5, 15.0)| 8.2 (6.6, 10.8)       | 13.3 (10.1, 18.1)         | <0.001       |
| Hb (g/L)          | 120.9 ± 22.6    | 123.3 ± 19.5          | 118.4 ± 25.4              | 0.11         |
| LVEF (%)          | 48.5 ± 9.8      | 51.7 ± 9.0            | 45.0 ± 9.5                | <0.001       |
| LVEDD (mm)        | 52.2 ± 7.1      | 50.5 ± 5.4            | 54.0 ± 8.2                | <0.001       |
| Mitral regurgitation (%) | 93 (42.7) | 45 (39.8) | 48 (45.7) | 0.38 |
| Ventricular aneurysm (%) | 54 (24.8) | 23 (20.4) | 31 (29.5) | 0.12 |
| Septal perforation (%) | 13 (6.0) | 0 (0) | 13 (12.4) | <0.001 |
| MVD (%)           | 91 (41.7)       | 51 (45.1)             | 40 (38.1)                 | 0.29         |

Data are expressed as mean ± SD, median (IQR) or number (percentage). CS: cardiogenic shock, PO2: oxygen partial pressure, PCO2: carbon dioxide partial pressure, Lac: lactate, TNI: cardiac troponin I, BNP: brain natriuretic peptide, WBC: white blood cell, Hb: hemoglobin, LVEF: left ventricular ejection fraction, LVEDD: left ventricular end-diastolic dimension, and MVD: multivessel disease.

Figure 1: The admission levels of BUN, creatinine, BUN-to-creatinine ratio, and GFR of survivors and nonsurvivors. Data were shown in median with IQR.
higher cumulative mortality within 30 days than patients with low BUN (all log-rank \( p < 0.001 \)).

Potential risk factors associated with 30-day mortality and MACE are listed in Table 3. Variables with a \( p \) value less than 0.05 in the univariate Cox regression analysis were included in the multivariate model. As a continuous variable, BUN was positively associated with an increased risk of 30-day mortality (HR 1.06, 95%CI 1.04–1.08, \( p < 0.001 \)). As a categorical variable, after adjustment, BUN \( > 8.95 \) mmol/L was identified as an important independent predictor for 30-day mortality (HR 2.08, 95%CI 1.28–3.36, \( p = 0.003 \)). Of note, GFR did not remain significant after adjustment. Other independent predictors for 30-day mortality included age (HR 1.03, 95%CI 1.01–1.05, \( p = 0.009 \)), SBP (HR 0.98, 95%CI 0.97–1.00, \( p = 0.01 \)), lactate >4.2 mmol/L (HR 2.59, 95%CI 1.66–4.04, \( p < 0.001 \)), BNP >400 pg/mL (HR 1.99, 95%CI 1.17–3.37, \( p = 0.01 \)), and LVEF \( \leq 50\% \) (HR 1.73, 95% CI 1.11–2.69, \( p = 0.02 \)). Also, as a continuous variable, BUN was positively associated with an increased risk of 30-day MACE (HR 1.04, 95%CI 1.02–1.06, \( p < 0.001 \)). As a categorical
variable, after multivariable adjustment, BUN > 8.95 mmol/L remained an independent predictor for 30-day MACE (HR 1.85, 95% CI 1.29–2.66, \( p < 0.001 \)). Only age (HR 1.02, 95% CI 1.00–1.03, \( p = 0.04 \)) and lactate > 4.2 mmol/L (HR 2.69, 95% CI 1.89–3.82, \( p < 0.001 \)) were also identified as predictors of 30-day MACE after CS.

The standard model for 30-day mortality prediction showed an AUC of 0.860, while the AUC of the new model increased to 0.878 when creatinine was replaced by BUN, as shown in Figure 5. Moreover, the IDI (0.053, \( p = 0.005 \)) and NRI (0.135, \( p = 0.010 \)) showed an improvement in the accuracy for mortality prediction of the new model when BUN was included, compared with the standard model of predictors in previous scores. The IDI and NRI are listed in Table 4, alongside their 95% CIs.

4. Discussion

The major findings of this study are as follows: firstly, in AMI patients who developed CS, admission BUN level was associated with short-term prognosis, and a BUN level higher than 8.95 mmol/L was an independent risk factor for 30-day mortality and 30-day MACE. Secondly, among BUN, creatinine, BUN-to-creatinine ratio, and GFR, BUN is the most effective predictor for short-term prognosis in AMI complicating CS. Thirdly, the prognostic value of BUN was comparable to traditional markers associated with CS. Finally, BUN may effectively add the accuracy of previous scoring systems of short-term mortality in CS. Our present study demonstrated the validity of BUN as a biomarker for prognostic evaluation in CS patients following AMI.

CS is a low-cardiac-output state resulting in life-threatening end-organ hypoperfusion and hypoxia, and AMI with left ventricular dysfunction remains the most common cause of CS [1, 2]. Despite the progress made in the reperfusion therapy, the in-hospital mortality of CS remains high. Therefore, identifying patients that developed CS at the high risk of death as soon as possible is one of the most crucial challenges facing the medical staff in the CCU. Although currently several risk scores for CS exist, the sophisticated algorithm and the variability of these scoring systems have limited their utility during practice [16–18].

BUN is a protein metabolic product generated mainly in the liver and excreted through the kidney, and traditionally, the serum BUN level represents the balance between urea production and renal excretion [19]. For decades, BUN has shown its value not only as a marker of renal damage but also a prognostic factor in many clinical conditions. During upper gastrointestinal bleeding, BUN is elevated because of enhanced urea production and can reflect the severity of bleeding [20]. In the general population of critically ill patients in ICU, BUN has demonstrated promise as a practical tool in acute decision making [21, 22]. Such prognostic value of BUN was also seen in acute ischemic stroke [23], acute decompensated or chronic heart failure [9, 24–26], and acute pulmonary embolism [27]. In patients with AMI, the BUN level was also found to be an important predictor of long-term mortality [28] However, to date, few data are available on the relationship between BUN and the outcomes in patients who developed CS after AMI. Our study confirmed that admission BUN level was independently associated with 30-day mortality and MACE in patients who developed CS after AMI.

The reason why BUN is associated with the short-term outcomes in patients with CS remains to be elucidated. However, several mechanisms may be addressed. In the
absence of enhanced production of urea, elevated BUN usually represents a decrease of GFR [6, 19]. In the setting of AMI, especially when CS occurs, multiple factors may contribute to the acute kidney injury (AKI) and result in the decrease of GFR and the increase of BUN. These factors include reduced cardiac output, systemic congestion, the activation of systemic vasoconstriction, the usage of angiotensin-converting enzyme inhibitors or diuretics, and sometimes, the administration of contrast media during revascularization [8, 29]. The elevations of BUN may occur even without the impairment of GFR. As urea reabsorption through proximal and distal tubules is a passive process linked to sodium and water reabsorption, conditions, such as insufficient cardiac output associated with water and sodium reabsorption may also lead to an increase of BUN. Therefore, the elevations of BUN may also represent the appropriate adjustment to the systemic hypoperfusion without substantial detriment to the kidney [7, 9, 24, 25]. CS patients are usually hypovolemic because of the reduced cardiac output, sweating, or sometimes severe vomiting, which could all result in elevated BUN. Therefore, elevated BUN, to some extent, also represents the relatively insufficient blood volume and concentrated blood, which, in turn, may increase the risk of adverse events.

The ROC analysis revealed that among BUN, creatinine, BUN-to-creatinine ratio, and GFR, BUN had the highest efficacy for predicting 30-day mortality and 30-day MACE. The observation was similarly seen in heart failure patients in some recent studies [9, 24–26]. Creatinine is freely filtered at the glomerulus and not reabsorbed, while urea is reabsorbed in both proximal and distal renal tubules. In the collecting duct, the urea reabsorption is flow-dependent so that more urea is reabsorbed as urine flows decrease [28]. Therefore, BUN may better reflect the cumulative hemodynamic effects and neurohormonal changes of severe heart failure than other renal markers in the setting of CS after AMI. Moreover, the predictive value of BUN was comparable to lactate, the widely known marker for organ hypoperfusion and an established predictor for mortality in CS [16, 30]. Such results indicate that the elevations of BUN and lactate reflect similar hemodynamic changes in CS.

After comparison, the optimal cut-off value for BUN to predict 30-day mortality in our study was 8.95 mmol/L, which was a practical value in critical CS patients and comparable to cut-offs identified in some other studies. Aronson et al. [28] proved that a BUN higher than 25 mg/dL (8.93 mmol/L) was an effective predictor for long-term mortality in AMI patients. In ICU, Bernhard Wernly et al. [21] identified 9.7 mmol/L as the optimal cut-off value for long-term mortality prediction in critically ill patients. Furthermore, studies have shown when patients were divided into more groups according to BUN levels in different situations, even subtle changes in BUN were associated with worse outcomes [22–25]. Such association was also seen in our Kaplan–Meier analysis when patients were divided into quartiles.

The NRI is a method that involves classifying patients into risk categories and determines how well a new model reclassifies patients into risk categories compared with the previous model [31]. The IDI calculation is another method to assess reclassification that does not rely on prespecified risk categories but represents a continuous measure [32]. Here, the addition of BUN to the traditional model not only improved the predictive power for 30-day mortality in CS patients (as assessed by AUC of ROC curve) but also the reclassification ability of subjects into different risk categories through NRI and IDI, indicating that BUN may effectively add the accuracy of previous scoring systems.

Our study has some clinical implications. Firstly, because of its convenience, efficiency, and low cost, admission BUN can provide initial risk stratification and prognostic evaluation. Secondly, the predictive value of admission BUN is superior to creatinine and GFR and comparable to some traditional markers, indicating its promising prognostic performance in CS complicating AMI. Putting BUN into the risk stratification model of CS may add the model’s accuracy. Finally, we believe monitoring BUN can help optimize management strategies, such as predicting the risk of continuous renal replacement therapy (RRT) because studies have shown elevated baseline BUN was associated with
increased risk of AKI in patients with postcardiotomy CS [33]. Recently, Gaudry et al. [34] found in severe AKI patients’ BUN concentration higher than 112 mg/dL (39.87 mmol/L) would mandate immediate RRT and longer postponing of RRT initiation did not confer an additional benefit and was associated with potential harm. Therefore, BUN may also play a role in guiding the future management of patients that require RRT.

This study also has some limitations. Firstly, since not all patients received a series of assaying the BUN value, we only analyzed the association of admission BUN level, with the short-term outcome, and dynamic change of BUN may provide better prognostic value. Secondly, BUN value was affected by many factors in addition to the cardiac or renal causes, and some factors were not considered in our present study. Last but not least, some confounders could not be ruled out because of

**Table 3:** Predictors for 30-day mortality and 30-day MACE by univariate and multivariate Cox analysis.

| Predictors for 30-day mortality | Univariate analysis | Multivariate analysis |
|---------------------------------|---------------------|----------------------|
|                                 | HR (95%CI)          | p value  | HR (95%CI) | p value  |
| Age, per 1-year increase        | 1.05 (1.03–1.06)    | <0.001   | 1.03 (1.01–1.05) | 0.009  |
| Male                            | 0.62 (0.42–0.92)    | 0.02     |            |          |
| SBP, per mmHg increase          | 0.98 (0.97–0.99)    | 0.03     | 0.98 (0.97–1.00) | 0.01   |
| Lac >4.2 mmol/L                 | 4.33 (2.87–6.56)    | <0.001   | 2.59 (1.66–4.04) | <0.001 |
| BNP >400 pg/mL                  | 3.83 (2.37–6.19)    | <0.001   | 1.99 (1.17–3.37) | 0.01   |
| BUN (continuous)                | 1.06 (1.04–1.08)    | <0.001   |            |          |
| BUN >8.95 mmol/L                | 4.09 (2.69–6.22)    | <0.001   | 2.08 (1.28–3.36) | 0.003  |
| GFR ≤55 mL/min/1.73 m²          | 3.53 (2.23–5.57)    | <0.001   |            |          |
| LVEF ≤50%                       | 2.64 (1.75–4.00)    | <0.001   | 1.73 (1.11–2.69) | 0.02   |

| Predictors for 30-day MACE      | Univariate analysis | Multivariate analysis |
|---------------------------------|---------------------|----------------------|
|                                 | HR (95%CI)          | p value  | HR (95%CI) | p value  |
| Age, per 1-year increase        | 1.02 (1.01–1.04)    | 0.001    | 1.02 (1.00–1.03) | 0.04   |
| Male                            | 0.88 (0.63–1.24)    | 0.47     |            |          |
| Lac >4.2 mmol/L                 | 3.23 (2.30–4.53)    | <0.001   | 2.69 (1.89–3.82) | <0.001 |
| BNP >400 pg/mL                  | 1.89 (1.35–2.66)    | <0.001   |            |          |
| BUN (continuous)                | 1.04 (1.02–1.06)    | <0.001   |            |          |
| BUN >8.95 mmol/L                | 2.63 (1.88–3.69)    | <0.001   | 1.85 (1.29–2.66) | 0.001  |
| GFR ≤55 mL/min/1.73 m²          | 2.17 (1.53–3.08)    | <0.001   |            |          |
| LVEF ≤50%                       | 1.80 (1.28–2.51)    | 0.001    |            |          |

SBP: systolic blood pressure, Lac: lactate, TNI: cardiac troponin I, BNP: brain natriuretic peptide, BUN: blood urea nitrogen, GFR: glomerular filtration rate, and LVEF: left ventricular ejection fraction.

**Figure 5:** The standard model for 30-day mortality prediction showed an AUC of 0.860, while the AUC of the new model increased to 0.878 when creatinine was replaced by BUN.
the retrospective and single-center nature of the study, which means more studies are required to further assess the predictive value of BUN in the setting of CS after AMI.

5. Conclusions
An admission BUN > 8.95 mmol/L was robustly associated with increased short-term mortality and MACE in patients with CS after AMI. The prognostic value of BUN was superior to other renal markers and comparable to traditional prognostic markers. This easily accessible index might be promising for early risk stratification in CS patients following AMI.

Data Availability
The data used to support the findings of this study are available from the corresponding authors upon request.

Disclosure
Bi Huang and Suxin Luo should be listed as co-corresponding authors.

Conflicts of Interest
The authors declare that they have no conflicts of interest.

Authors’ Contributions
Yuansong Zhu designed the study, analyzed the data, and drafted the manuscript. Bryan Richard Sasmita, Xiankang Hu, Yuzhou Xue, Hongbo Gan, Zhenxian Xiang, and Yi Jiang participated in the data collection. Bi Huang coordinated the process and revised the manuscript. Suxin Luo provided funding and supervised. All authors take responsibility for all aspects of the reliability of the data presented and their discussed interpretation.

Acknowledgments
The authors thank all the patients who were enrolled in the study. This study was supported by National Key R&D Program of China (2018YFC1311400 and 2018YFC1311404).

References
[1] C. Vahdatpour, D. Collins, and S. Goldberg, “Cardiogenic shock,” Journal of the American Heart Association, vol. 8, no. 8, Article ID e011991, 2019.
[2] S. van Diepen, J. N. Katz, N. M. Albert et al., “Contemporary management of cardiogenic shock: a scientific statement from the American heart association,” Circulation, vol. 136, no. 16, pp. e232–e268, 2017.
[3] D. Acharya, “Predictors of outcomes in myocardial infarction and cardiogenic shock,” Cardiology in Review, vol. 26, no. 5, pp. 255–266, 2018.
[4] K. Damman, M. A. E. Valente, A. A. Voors, C. M. O’Connor, D. J. van Veldhuisen, and H. L. Hillege, “Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis,” European Heart Journal, vol. 35, no. 7, pp. 455–469, 2014.
[5] H. F. AlFaleh, A. O. Alsuwaida, A. Ullah et al., “The prognostic impact of in-hospital worsening of renal function in patients with acute coronary syndrome,” International Journal of Cardiology, vol. 167, no. 3, pp. 866–870, 2013.
[6] N. Baum, C. C. Dickos, and C. E. Carlton, “Blood urea nitrogen and serum creatinine,” Urology, vol. 5, no. 5, pp. 583–588, 1975.
[7] J. Lindenfeld and R. W. Schrier, “Blood urea nitrogen,” Journal of the American College of Cardiology, vol. 58, no. 4, pp. 383–385, 2011.
[8] A. Kazory, “Emergence of blood urea nitrogen as a biomarker of neurohormonal activation in heart failure,” The American Journal of Cardiology, vol. 106, no. 5, pp. 694–700, 2010.
[9] X. Ren, W. Qu, L. Zhang et al., “Role of blood urea nitrogen in predicting the post-discharge prognosis in elderly patients with acute decompensated heart failure,” Scientific Reports, vol. 8, no. 1, p. 13507, 2018.
[10] J. S. Hochman, L. A. Sleeper, J. G. Webb et al., “Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK investigators should we emergently revascularize occluded coronaries for cardiogenic shock,” The New England Journal of Medicine, vol. 341, no. 9, pp. 625–634, 1999.
[11] K. Thygensen, J. S. Alpert, A. S. Jaffe et al., “Fourth universal definition of myocardial infarction (2018),” Circulation, vol. 138, no. 20, pp. e618–e651, 2018.
[12] A. S. Levey, L. A. Stevens, C. H. Schmid et al., “A new equation to estimate glomerular filtration rate,” Annals of Internal Medicine, vol. 150, no. 9, pp. 604–612, 2009.
[13] B. Levy, O. Bastien, B. Karim et al., "Experts’ recommendations for the management of adult patients with cardiogenic shock," *Annals of Intensive Care*, vol. 5, no. 1, p. 52, 2015.

[14] H. Thiele, E. M. Ohman, S. Desch, I. Eitel, and S. de Waaha, "Management of cardiogenic shock," *European Heart Journal*, vol. 36, no. 20, pp. 1223–1230, 2015.

[15] J. M. Cheng, A. M. Helming, L. C. van Vark et al., "A simple risk chart for initial risk assessment of 30-day mortality in patients with cardiogenic shock from ST-elevation myocardial infarction," *European Heart Journal: Acute Cardiovascular Care*, vol. 5, no. 2, pp. 101–107, 2016.

[16] J. Pöss, J. Köster, G. Fuernau et al., "Risk stratification for patients in cardiogenic shock after acute myocardial infarction," *Journal of the American College of Cardiology*, vol. 69, no. 15, pp. 1913–1920, 2017.

[17] M. ˙Ilker Hayıro˘glu, M. Keskin, A. Okan Uzun et al., "Predictors of in-hospital mortality in patients with ST-segment elevation myocardial infarction complicated with cardiogenic shock," *Heart Lung & Circulation*, vol. 28, no. 2, pp. 237–244, 2019.

[18] L. Obling, M. Frydland, R. Hansen et al., "Risk factors of late cardiogenic shock and mortality in ST-segment elevation myocardial infarction patients," *European Heart Journal: Acute Cardiovascular Care*, vol. 7, no. 1, pp. 7–15, 2018.

[19] H. Wang, J. Ran, and T. Jiang, "Urea," *Subcellular Biochemistry*, vol. 73, pp. 7–29, 2014.

[20] M. Tomizawa, F. Shinozaki, R. Hasegawa et al., "Patient characteristics with high or low blood urea nitrogen in upper gastrointestinal bleeding," *World Journal of Gastroenterology*, vol. 21, no. 24, pp. 7500–7505, 2015.

[21] B. Wernly, M. Lichtenauer, N. A. R. Vellinga et al., "Blood urea nitrogen (BUN) independently predicts mortality in critically ill patients admitted to ICU: a multicenter study," *Clinical Hemorheology and Microcirculation*, vol. 69, no. 1-2, pp. 123–131, 2018.

[22] O. Arihan, B. Wernly, M. Lichtenauer et al., "Blood urea nitrogen (BUN) is independently associated with mortality in critically ill patients admitted to ICU," *PLoS One*, vol. 13, no. 1, Article ID e0191697, 2018.

[23] S. You, D. Zheng, C. Zhong et al., "Prognostic significance of blood urea nitrogen in acute ischemic stroke," *Circulation Journal*, vol. 82, no. 2, pp. 572–578, 2018.

[24] D. Aronson, M. A. Mittleman, and A. J. Burger, "Elevated blood urea nitrogen level as a predictor of mortality in patients admitted for decompensated heart failure," *The American Journal of Medicine*, vol. 116, no. 7, pp. 466–473, 2004.

[25] J. Khoury, F. Bahouth, Y. Stabhholz et al., "Blood urea nitrogen variation upon admission and at discharge in patients with heart failure," *ESC Heart Failure*, vol. 6, no. 4, pp. 809–816, 2019.

[26] C. A. Cauthen, M. J. Lipinski, A. Abbate et al., "Relation of blood urea nitrogen to long-term mortality in patients with heart failure," *The American Journal of Cardiology*, vol. 101, no. 11, pp. 1643–1647, 2008.

[27] M. A. Tatlisu, A. Kaya, M. Keskin et al., "The association of blood urea nitrogen levels with mortality in acute pulmonary embolism," *Journal of Critical Care*, vol. 39, pp. 248–253, 2017.

[28] D. Aronson, H. Hammerman, R. Beyar et al., "Serum blood urea nitrogen and long-term mortality in acute ST-elevation myocardial infarction," *International Journal of Cardiology*, vol. 127, no. 3, pp. 380–385, 2008.

[29] A. J. Kirtane, D. M. Leder, S. S. Waikar et al., "Serum blood urea nitrogen as an independent marker of subsequent mortality among patients with acute coronary syndromes and normal to mildly reduced glomerular filtration rates," *Journal of the American College of Cardiology*, vol. 45, no. 11, pp. 1781–1786, 2005.

[30] V.-P. Harjola, J. Lassus, A. Sionis et al., "Clinical picture and risk prediction of short-term mortality in cardiogenic shock," *European Journal of Heart Failure*, vol. 17, no. 5, pp. 501–509, 2015.

[31] A. C. Alba, T. Agoritsas, M. Walsh et al., "Discrimination and calibration of clinical prediction models," *JAMA*, vol. 318, no. 14, pp. 1377–1384, 2017.

[32] K. Hayashi and S. Eguchi, "The power-integrated discriminant improvement: an accurate measure of the incremental predictive value of additional biomarkers," *Statistics in Medicine*, vol. 38, no. 14, pp. 2589–2604, 2019.

[33] X. Ding, H. Xie, F. Yang, L. Wang, and X. Hou, "Risk factors of acute renal injury and in-hospital mortality in adult patients with postcardiotomy cardiogenic shock requiring veno-arterial extracorporeal membrane oxygenation: utility of MELD-XI score," *Perfusion*, Article ID 2676591211006619, 2021.

[34] S. Gaudry, D. Hajage, L. Martin-Lefevre et al., "Comparison of two delayed strategies for renal replacement therapy initiation for severe acute kidney injury (AKIKI 2): a multicentre, open-label, randomised, controlled trial," *The Lancet*, vol. 397, no. 10281, pp. 1293–1300, 2021.